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INTRODUCTION 
 
One of the main characteristics of the immune system is the "immunological 
memory" that is the possibility, following exposure to a specific antigen, to enhance 
the future ability to respond to that same antigen with a faster and more intense 
secondary immune response. This immune memory is guaranteed as both B and T 
memory cells are more efficient than virgin cells. 
In the T lymphocyte group, the naïve T-cells, once activated by a specific antigen, 
undergo a huge clonal expansion and at the same time differentiate into a short-
lived effector, which generally dies at the end of the immune response, and in long-
lived memory T-cells, ready to provide protection in case of new contact with the 
same antigen.  
These memory T-cells can be localized in any part of the body, with a particular 
preference for the bone marrow, in which they remain for a long time with the 
ability to recirculate. In the group of memory T-cells, two subgroups are 
distinguished, in relation to the phenotype and functional potential: the "central 
memory cells (TCM)", which express the CCR7 chemokine receptor at high 
intensity, and the " effector memory T cells (TEM) "which do not express CCR7. In 
the panorama of lymphocyte T memory we can also find a group of non-circulating 
resident memory T cells (TRM), which live permanently in some peripheral tissues 
and where they survive in a state of quiescence. 
It appears that circulating memory T cells are responsible for systemic immunity, 
while TRM cells represent immediate protection in the main pathogen entry sites, 
mostly participating in local defence. 
Several studies have shown that bone marrow (BM) is included among the organs 
in which TRM cells can be observed. 
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In fact, BM is considered to be the largest T-cell memory maintenance site, since it 
has a high frequency of antigen-specific T memory lymphocytes against vaccines, 
pathogens and several tumor antigens. The BM in this case provides survival 
signals, making the interaction with stromal cells expressing homeostatic cytokines, 
such as IL-7 or IL-15. BM TRM cells are phenotypically characterized by the 
expression of CD69 and by the integrins CD103 and VLA1, molecules that 
contribute to the localization of these cells in the tissues.  
In recent years, we have also learned that TRM can contribute to the defence of the 
host in the neoplastic conditions, representing potentially reactive cells against 
hematological tumors infiltrating the bone marrow. For example, this has been 
proven in some studies of "adoptive BM T-cell therapy" in multiple myeloma 
cases. 
In relation to the latter topic and to the possibility that TRM cells may have a role in 
the immunological surveillance in the course of neoplasms, including plasma cell 
dyscrasias, we conducted a study aimed at the description and functional analysis of 
bone marrow TRM in patients with new diagnosis of multiple myeloma. 
The aim of this study is to evaluate the frequency and phenotype of CD8 + memory 
T lymphocytes resident in the BM of patients with multiple myeloma. In fact, the 
CD8+ TRM could represent a source of tumor-specific effector cells capable of 
controlling tumor growth. In this case, they can provide an immunological marker 
of prognosis of the pathology or, even more, they can become a specific target in 
the context of the most modern immunotherapy. 	 	
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1. MULTIPLE MYELOMA AND IMMUNOTHERAPY 
1.1 Multiple Myeloma 
 Multiple myeloma (MM) is a malignant neoplasm characterized by the 
clonal expansion of plasma cells that can release monoclonal immunoglobulins 
(protein M, or paraprotein or monoclonal component), or their fractions (free light 
chains, FLC) [1].  
MM is part of a broader spectrum of diseases called "plasma cell dyscrasias" or 
"plasma cell disorders", which include other conditions such as monoclonal 
gammopathy of undetermined significance, smoldering multiple myeloma, solitary 
plasmacytoma, Waldenström's macroglobulinemia, amyloidosis AL and POEMS 
syndrome. 
All plasma cell dyscrasias are characterized by the accumulation and expansion of 
monoclonal plasma cells. In most cases, these pathological plasma cells maintain 
the ability to produce and release immunoglobulins or parts of them with the 
production therefore of identical Ig.  	
1.1.1 Epidemiology 	 MM accounts for 1.7% of all cancers and 10% of all hematological 
malignancies in the United States. However, globally the incidence varies and is 
higher in more developed countries such as the United States and Europe; 
moreover, the incidence is 2-3 times higher in black than in white people, although 
it is lower in Asians and Hispanics [2].  
Most patients are between 65 and 74 years old at the time of diagnosis, with an 
average age of 69. Only 4% of cases concern subjects under the age of 45. Men are 
more affected than women (1.6: 1). 
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The prevalence of MM has increased compared to the past, due to the improvement 
of diagnostic techniques and the increase in survival (an ever increasing use of 
autologous transplantation and development of new therapeutic agents) [3].  
Several epidemiological studies have shown that there is a greater predisposition to 
MM development (up to 4 times) in the first-degree relatives of individuals 
suffering from plasma cell dyscrasias [4]. Furthermore, there is also a correlation 
with other hematological malignancies; a recent study has shown the existence of 
common biological pathways that determine the development of MM and chronic 
lymphatic leukemia (LLC) [5]. 
Among the environmental factors, some studies have shown an association between 
MM and body mass index: in obese people, adipocytes secrete greater quantities of 
IL-6 and IGF-1, that are useful for the growth and survival of myeloma cells [6]. 
Another hypothesis suggests a possible role of chronic immune stimulation such as 
occurs during allergies, infections (HIV, HCV) or other autoimmune disorders [7]. 
 
1.1.2 Pathogenesis, genetic alterations and bone marrow microenvironment 
It is believed that the development of MM is a multistep process, characterized by 
the initial establishment of specific genetic lesions in neoplastic cells, the formation 
of a privileged relationship with the marrow microenvironment (that contributes to 
the growth, survival, migration and drug resistance of myeloma cells) and the 
subsequent appearance of further genetic aberrations that make the neoplastic clone 
independent of external factors for its own expansion. 
In fact, it seems possible to postulate that all patients diagnosed with MM have had 
a previous phase corresponding to a condition of monoclonal gammopathy of 
uncertain significance (MGUS) [8, 9]. This can remain stable for years or it can 
progress through the phases of asymptomatic or smoldering MM (SMM), in which 
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there are still no signs of organ damage, as far as the symptomatic MM. The final 
evolution may be the loss of dependence on the marrow microenvironment, with 
the dissemination of myeloma cells in the blood circulation (plasma cell leukemia) 
or the invasion of other tissues (extramedullary myeloma). 
MM is a heterogeneous disease with a complex genetic background characterized 
by anomalies in the karyotype, chromosomal translocations and gene duplications 
or deletions. 
The first genetic "event" of the aforementioned multistep process could occur 
during the isotype switch process with translocations involving the IgH locus (the 
locus containing the heavy chain gene) on chromosome 14q32. These 
translocations are considered primary events since they are found with the same 
frequency in both MGUS and MM. 
The MM clone, for its instability, can undergo further modifications (secondary 
genetic anomalies) over time. 
On the basis of the chromosomal kit it is possible to divide patients with MM into 
two groups: hyperdiploid MM and non-hyperdiploid MM. 
Hyperdiploid patients show trisomies in chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 
and generally have a more favourable prognosis. In non-hyperdiploid MM, 
translocations commonly involving the loci of heavy chains or, less frequently, 
light chains.  
The most frequent translocations involving the 14q32 locus are 11q13 (15%), 4p16 
(15%), 16q23 (5%), 20q11 (2%) and 6p21 (5%), while the genes involved are those 
of cyclin D1, cyclin D3, the MMSET / FGFR3 genes and the c-MAF gene [8]. 
The deletion of chromosome 13, deletion of chromosome 17p13 and amplification 
of chromosome 1q21 are the most frequent genetic aberrations. 
The presence of the 1p23 deletion is important, especially for the prognosis [10]. 
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In conclusion, other genetic alterations could be present in the MM pathogenesis 
such as N- and K-Ras mutations, involved in the activation of the NF-kB pathway 
[11] and the activity of small non-coding RNAs, called microRNAs (miRNAs) with 
an important role in the regulation of oncogenes and therefore in neoplastic 
transformation [12]. 
The BM microenvironment certainly plays a fundamental role in the development 
and maintenance of the plasma cell clone. It consists of an extracellular 
compartment (matrix) consisting of proteins, such as collagen, laminin, fibronectin, 
and numerous hematopoietic and non-haemopoietic cells (medullary stromal cells), 
such as osteoblasts, osteoclasts, fibroblasts and immune effector cells. Plasma cells 
are recalled to the BM through a homing process driven by the CXCL12 / SDF-1 
chemokine produced by stromal cells [13]. Once in the BM, the plasma cells, 
through cell-cell reciprocal interactions (homotypic or heterotypic) and cell-matrix, 
survive, proliferate and become chemoresistant. 
A crucial role is played by IL-6, produced by stromal cells and, partly, MM cells 
[14], but there are many cytokines involved and one of the most activated molecular 
pathways is the NF-κB pathway (nuclear factor κB) [15].  
The formation of new vessels induced by VEGF satisfies both the nutritional intake 
and the transmission of further cytokines; an increased microvascular density 
(microvessel density, MVD) in BM appears to correlate with disease progression 
and with a poorer prognosis [16]. 
 
1.1.2 Diagnosis and Staging 
The International Myeloma Working Group (IMWG) updated the MM diagnostic 
criteria in 2014 [17]. The diagnosis requires a quantity of plasma cells in the BM ≥ 
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10% or the presence of a bone or extramedullary plasmocytoma associated with one 
of the following myeloma-defining events (MDE): 
• Evidence of organ damage. The main clinical manifestations are 
summarized in the English acronym CRAB: hyperCalcemia, Renal failure, 
Anemia and Bone lesions; 
• One of the following biomarkers of malignancy (SLiM criteria):  
- Quantity of BM plasma cells ≥ 60%; 
- Serum free light chains ratio (rFLC) (involved/not involved) ≥ 100 
(the chain involved must be present in an amount greater than 100 
mg / L);) ≥ 100 
- ≥ 1 focal lesion in MRI (each of which must be ≥ 5mm). 
In most cases, the key element supporting the suspected diagnosis is the finding of 
a monoclonal component (MC) in serum and/or urine. The monoclonal peak is 
shown at the serum proteins electrophoresis as a net band in the γ region, more 
rarely in the β or 2 regions (Fig. 1). 	
 
Fig. 1. Serum protein electrophoresis of a patient with MM. The monoclonal component, 
located in the γ area, is equal to 5.04 g dL. 
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Once the presence of the monoclonal peak at the electrophoresis is underlined, the 
nature of the secreted immunoglobulin (typing or immunological characterization) 
is confirmed with the electrophoretic immunofixation (IFE) or with the 
immunosottration (ISE), more specific and sensitive technique of the 
electrophoresis. Not all MM isotypes have the same incidence: 52% is IgG, 21% is 
IgA, 16% is a micromolecular or light chain MM (LCMM), 2% is bi-clonal (the 
light chain or heavy chain may be different) and 0.5% is IgM; IgD and IgE MM are 
rare [18]. Furthermore, a percentage of patients may present an oligosecreting MM 
or a non-secretory MM, in which the MC is null. In these last two groups of 
patients it may be useful to evaluate the serum rFLC; in fact, an unbalanced ratio 
indicates the presence of a clonal disorder [19]. 
Furthermore, a reduction in γ-globulin not included in the monoclonal peak may be 
evident; this phenomenon can be evaluated more precisely by measuring serum 
immunoglobulins (IgM, IgG, IgA) with a reduction in the non-clonal type 
(phenomenon of retroinhibition or immunoparesis) [20].  
The 24-hour urine collection and its study can reveal the presence of a Bence-Jones 
proteinuria (PBJ) that is the presence of significant urinary FLC. For the PBJ 
research, urine immunofixation is used and this is the only one with which it is 
possible to ascertain the two characteristics of the PBJ: the monoclonality and the 
absence of the heavy chain. 
The blood count can show normochromic anemia, leukopenia and/or 
thrombocytopenia. Blood tests show an increase in serum calcium, urea, uraemia, 
creatinine, LDH and β2-microglobulin (B2M). The latter is important in terms of 
prognostic stratification; its levels related to the stage of myeloma and survival [21, 
22]. The MM diagnosis also requires the bone marrow assessment.    
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MM cells express CD38 and CD138 on their surface and, unlike normal ones, 
present a weak or absent expression of CD19, CD27, CD45, and CD81 and 
elevated levels of CD28, CD33 and CD56. Sometimes they can express CD20 and 
CD117 aberrantly [23, 24]. From a histological point of view, the neoplastic infiltrate 
can develop with a widespread growth pattern, or it can be distributed in the 
interstice or organized into nodules (patchy). 
The bone damage present in MM patients can be evidenced by several radiological 
investigations. Traditional radiography allows the detection of lytic lesions or 
diffuse osteopenia when the loss of trabecular bone exceeds 50% of the basal 
values. For this reason, it has been supplanted by the much more sensitive skeleton 
CT at low doses. The lesions are variable, from osteoporosis to the presence of 
crushed and deformed vertebral bodies due to vertebral collapses, but the typical 
alteration is that of an osteolytic lesion lacking the usual peripheral radiopaque 
osteo-thickening oracle. It is also useful to combine CT/PET with 18F-FDG, in 
particular to evaluate the presence of extramedullary disease. The risk of 
pathological fractures or neurological compression should be assessed in patients 
with osteolytic lesions. In this sense, MRI is preferred for revealing medullary 
compressions. 
Obviously, monoclonal plasma cellular disorders must be distinguished from the 
polyclonal forms of marrow plasmacytosis that can occur in autoimmune disorders, 
chronic liver diseases, chronic infections and AIDS. 
The variable outcome of patients with MM depends on biological differences, 
tumor load and patient characteristics. In MM staging, the use of the Durie and 
Salmon classification, which allowed the estimate of the burden of disease based on 
the magnitude of the neoplastic mass and the extension of the terminal organ 
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damage of the host, was adopted for years [25]. This allowed defining disease stages 
with distinct expectations of survival. 
More recently, a new staging system (ISS) has been introduced into clinical 
practice. It is based on the concentrations of β2-microglobulin and albumin at the 
time of diagnosis. The patients are then divided into three prognostic groups related 
to progressively lower overall survival [26]. The ISS was amended in 2015 by 
adding the genetic risk assessment by FISH and the LDH values [27]. The ISS and 
R-ISS provide prognostic information at diagnosis but have not been validated in 
relapsed or refractory MM. 
 	
STAGE	 DS	 ISS	 R-ISS	
	
	
	
	
I	
All of the following: 
- Hb > 10 mg/dl 
- Serum calcium 
normal or ≤ 12 mg/dl 
- Bone x-ray: normal 
bone structure (scale 
0) or solitary bone 
plasmacytoma only 
- Low M-component 
production rate: IgG 
<5 g/dl, IgA < 3 g/dl 
and Bence-Jones 
protein < 4 g/24 hours	
- Serum B2M ≤ 3,5 
g/dl 
- Serum albumin ≥ 3,5 
g/dl	
- ISS I 
- Standard-risk 
chromosomal 
abnormalities* 
- Normal LDH	
	
II	
 
Neither stage I nor 
stage III	  Neither stage I nor stage III according to 
the following 
subcategories: 
• Serum B2M < 
3,5 g/d and 
serum 
albumin < 3,5 
g/dl; 
• Serum B2M 
3,5 - 5,5 g/dl 
irrespective 
of serum 
albumin level 
	
	
	
	
III	
One or more of the 
following: 
- Hb < 8,5 g/dl 
- Serum calcium > 12 
mg/dl 
- Advanced lytic bone 
lesions (scale 3) 
- Serum B2M ≥ 5,5 
g/dl	 - ISS III - High-risk 
chromosomal 
abnormalities ** 
- High LDH 	
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- High M-component 
production rate: IgG > 
7 g/dl, IgA > 5 g/dl 
and Bence-Jones 
protein > 2 g/24 hours		 	 	 	 A: creatinine > 2mg/dl 
B: creatinine ≥2mg/dl	 	 	
 
Table 1. Staging systems DS, ISS e R-ISS 
 *Standard-risk chromosomal abnormalities= absence of high-risk chromosomal abnormalities 
 ** High-risk chromosomal abnormalities = del(17p) e/o t(4;14) e/o t(14;16)		
 
An adequate therapeutic choice also depends on the patient characteristics, and for 
this reason, a correct evaluation of the latter should always be considered. In 2016, 
the IMWG published the result of a study conducted on 869 patients with a new 
diagnosis of MM, all undergoing a pre-treatment geriatric assessment. This study 
demonstrated not only age but also the comorbidity burden and the performance 
status of patients in everyday life are variables able to stratify three distinct groups 
of patients, each of which characterized by a different tolerance to the treatment and 
a different survival outcome [28]. The comorbidity burden was assessed by the 
Charlson comorbidity index (CCI), while the ADL and IADL scales defined the 
performance status. A score was then defined (later nicknamed "Frailty score") 
consisting of four variables: age, CCI, ADL and IADL. This score stratified the 
patients into three groups: fit, intermediate fit and frail. Compared to fit patients, 
those defined as “frail” have a higher, statistically significant, probability of facing 
non-haematological adverse events and death and/or disease progression. 
 
1.1.3 General information on treatment 
Despite the considerable progresses made in recent years in the therapeutic field, 
MM remains today an incurable disease, characterized by an alternation of latency 
and recurrence phases, with a chronic course of the pathology. 
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At the moment, only the symptomatic MM or associated with one of the biological 
markers (MDE) must be treated. 
Once the need for an anti-myeloma treatment has been ascertained, the patient is 
subjected to a first line therapy; it is followed by remission periods of varying 
lengths, based on the effectiveness of the treatment itself. Almost inevitably, 
however, the plasma cell clone returns to proliferate, thus configuring a recurrent 
disease.  
Subsequent to a possible second line therapy there is a new period of remission, the 
length of which is widely variable and dependent on several factors. 
In the early 1980s, the combination of vincristine, doxorubicin, and dexamethasone 
(VAD) was used as standard induction therapy. Today MM therapy has 
significantly changed through the use of new drugs, which work differently from 
traditional drugs. Among these there are proteasome inhibitors (Bortezomib, 
Carfilzomib, Ixazomib), immunomodulating drugs (Thalidomide, Lenalidomide, 
Pomalidomide), inhibitors of histone deacetylases (Panobinostat) and monoclonal 
antibodies directed against molecules expressed on the surface of plasma cells 
(Daratumumab, Elotuzumab).  
The central issue in choosing the correct therapy is the eligibility of patients for 
autologous stem cell transplantation (ASCT). The choice depends on the patient's 
age, comorbidities and performance status. 
Patients under 65 years old and fit patients under 70 years old (normal cardiac, 
pulmonary and hepatic function) are considered suitable for autologous 
transplantation. 
Maintenance therapy, on the other hand, is aimed at maintaining the response 
obtained with a treatment at low dosages for longer. 
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Patients older than 65-70, not eligible for transplantation, undergo chemotherapy 
regimens, with the dosage modified according to the patient's frailty. 
A refractory MM is a disease that has not presented at least a partial response to 3 
or more cycles of anti-myeloma therapy or that has progressed within 60 days of 
the last treatment. 
On the other hand, we define a relapsed MM as a disease that requires a new rescue 
therapy after a partial or complete remission interval of at least 60 days. The latter 
is defined as "biochemical relapse" in the presence of plasma cell proliferation and 
the consequent increase in the monoclonal blood and urine component; or it is 
defined "clinical relapse" when it follows the appearance of new symptoms. The 
IMWG guidelines recommend starting a new therapy line in cases of clinical 
recurrence or "aggressive" biochemical recurrence, i.e. characterized by a rapid 
increase in the monoclonal component. 
It is clear that a correct evaluation of the treatment response is essential in MM 
management. In 2016, the IMWG criteria for response and definition of the 
minimum residual disease (MRD) were updated (Table 2). 
A fundamental part of the patient's therapy with MM is the so-called supportive 
therapy. In fact, as highlighted, the manifestations occur at systemic level and 
determine a multi-organ involvement. 
Bisphosphonates (BSF) are the primary therapeutic aid in the treatment of bone 
disease. Denosumab, an antibody against RANK-L, can also be used in the 
prevention of SRE in patients with MM [29]. Orthopedic surgery must be considered 
in the event of fractures to long bones, instability or vertebral collapses with spinal 
or radicular compression. Both vertebroplasty and kyphoplasty give good analgesic 
and biomechanical results [30]. Radiation therapy, on the other hand, is useful for 
analgesic purposes and for skeletal localizations of disease at risk of fracture [31].	
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Table 2. International Myeloma Working Group consensus criteria for response and 
minimal disease assessment in multiple myeloma 
Response category	 Response criteria	
Complete Response (CR)	
Negative immunofixation on the serum and 
urine and disappearance of any soft tissue 
plasmacytomas and < 5% plasma cells in bone 
marrow	
Complete Response stringent (sCR)	
CR as defined below plus normal FLC ratio and 
absence of clonal cells in bone marrow3 by 
immunohistochemistry or immunofluorescence 
Very Good Partial Response (VGPR)	
Serum and urine M-protein detectable by 
immunofixation but not on electrophoresis or > 
90% reduction in serum M-protein plus urine 
M-protein level < 100 mg/24 h	
Partial Response (PR)	
> 50% reduction of serum M-protein and 
reduction in 24 hours urinary M-protein by 
>90% or to < 200 mg/24 h. If the serum and 
urine M-protein are unmeasurable,5 a > 50% 
decrease in the difference between involved and 
uninvolved FLC levels is required in place of 
the M-protein criteria 
If serum and urine M-protein are not 
measurable, and serum free light assay is also 
not measureable, > 50% reduction in plasma 
cells is required in place of M-protein, provided 
baseline bone marrow plasma cell percentage 
was > 30% 
In addition to the above listed criteria, if present 
at baseline, a > 50% reduction in the size of soft 
tissue plasmacytomas is also required	
Stable Disease (SD)	 Not meeting criteria for CR, VGPR, PR, or progressive disease	
Progressive Disease (PD)	
Increase of > 25% from lowest response value 
in any one or more of the following: 
  
• Serum M-component and/or 
(the absolute increase must be 
> 0.5 g/dL)  
• Urine M-component and/or 
(the absolute increase must be 
> 200 mg/24 h) 
• Only in patients without 
measurable serum and urine 
M-protein levels; the 
difference between involved 
and uninvolved FLC levels. 
The absolute increase must be 
> 10 mg/dL 
• Bone marrow plasma cell 
percentage; the absolute 
percentage must be > 10% 
• Definite development of new 
bone lesions or soft tissue 
plasmacytomas or definite 
increase in the size of existing 
bone lesions or soft tissue 
plasmacytomas; 
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• Development of 
hypercalcemia (corrected 
serum calcium > 11.5 mg/dL 
or 2.65 mmol/L) that can be 
attributed solely to the plasma 
cell proliferative disorder 
 
	 	
“Sustained MRD-negative”	
MRD negativity in the marrow (NGF or NGS, 
or both) and by imaging as defined below, 
confirmed minimum of 1 year apart. Subsequent 
evaluations can be used to further specify the 
duration of negativity (e.g., MRD-negative at 5 
years) 
“Flow MRD-negative”	
Absence of phenotypically aberrant clonal 
plasma cells by NGF on bone marrow aspirates 
using the EuroFlow standard operation 
procedure for MRD detection in multiple 
myeloma (or validated equivalent method) with 
a minimum sensitivity of 1 in 105 nucleated 
cells or higher 
“Sequencing MRD-negative”	
Absence of clonal plasma cells by NGS on bone 
marrow aspirate in which presence of a clone is 
defined as less than two identical sequencing 
reads obtained after 
DNA sequencing of bone marrow aspirates 
using the LymphoSIGHT platform (or validated 
equivalent method) with a minimum sensitivity 
of 1 in 105 nucleated cells or higher 
“Imaging-positive MRD-negative”	
MRD negativity as defined by NGF or NGS 
plus disappearance of every area of increased 
tracer uptake found at baseline or a preceding 
PET/CT or decrease to less mediastinal blood 
pool SUV or decrease to less than that of 
surrounding normal tissue 			
1.2. Immunotherapy in Multiple Myeloma  
 
 In the last 20 years, the introduction of autologous stem cell transplantation, 
followed by proteasome inhibitors and immunomodulatory agents increased the 
survival of MM patients by 50%. However, a high proportion of patients relapse 
and become refractory, especially patients with adverse cytogenetic. 
 Therefore, novel strategies, such as immunotherapy, have been developed in the 
last few years to improve the survival of these patients. Immunotherapy treatments 
include a high number of different strategies used to attack the tumor cells by using 
the immune system. 
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 Interestingly, immunotherapy has arisen as a new modality treatment with very 
promising results and less toxic effects. Recent drugs include the next generation of 
PIs (carfilzomib, ixazomib, marizomib, and oprozomib), small and targeted 
molecules such as histone deacetylase inhibitors, venetoclax, selinexor, Hsp90 
inhibitors and PI3K/AKT/mTOR inhibitors, which are currently under 
development. Immunotherapy also includes other treatments, such as monoclonal 
antibodies, bi-specific T cell engaging antibodies (BiTEs), bi-specific antibodies, 
antibody-drug conjugates (ADC), immune checkpoint inhibitors and adoptive cell 
immunotherapy. A specific strategy includes the immunotherapy treatment based 
on antibodies that target antigens expressed on tumor cells. Whereas normal plasma 
cells express CD38, CD138, CD19 and CD45, malignant PCs loose CD45 and 
CD19 and usually acquire high expression of CD56 and CD117 [32]. 
 The panel of surface plasma cell markers includes CD150 (SLAMF1), CD48 
(SLAMF2), CD229 (SLAMF3), CD352 (SLAMF6), CD319 (SLAMF7 or CS1), 
CD272, CD86, CD200, and CD184. Therefore, they could be possible targets for 
immunotherapy.  
 Bi-Specific T-Cell Engagers Antibodies (BiTEs) and Bi-Specific Antibodies have 
shown promising results in the treatment of R/R MM in pre-clinical studies. BiTEs 
are designed to bind a tumor cell and an immune cell by engaging usually CD3 
with an antigen expressed in the tumor cell. Consequently, the T cell becomes 
activated and attacks the target cell. There are different BiTEs targeting BCMA and 
CD3, which have shown potent anti-MM activity in vitro and in vivo murine and 
monkey models of MM [33].  
Also bi-specific antibodies are being tested for the treatment of MM. NKG2D is an 
activating receptor expressed on NK cells, CD8+ T cells, γδ T cells and NKT cells. 
Simultaneous targeting of NKG2D and CS1 should engage both innate and 
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adaptive immune cells to target MM cells and to show in vitro and in vivo anti-MM 
activity.  
Immune checkpoints are negative signals established between immune and tumor 
cells that hamper immune cells and prevent them from eliminating malignant cells. 
Antibodies such as ipilimumab, which blocks CTLA-4, pembrolizumab and 
nivolumab, which block PD-1 in T cells, and atezolizumab, durvalumab and 
avelumab, which block PD-L1 on tumor cells, have been developed and approved 
by the FDA for solid tumors. However, targeting immune checkpoints has not been 
very successful in MM as of yet. 
Genetically modifying autologous T cells to express chimeric antigen receptors 
(CARs) thus redirecting them to eliminate tumor cells or other harmful cells is a 
new and revolutionary therapeutic modality for cancer treatment [34]. 
The success of new CAR T cell therapies relies on selecting the right antigen to 
target. The antigen should be expressed broadly in tumors of a given type, but 
should not be present in healthy tissues, as to avoid off-target effects and associated 
toxicity. There are currently 32, completed or on-going, clinical trials involving 
CAR T cell therapy in MM and the vast majority of them are evaluating the 
efficacy of anti-BCMA CAR and a few assessing anti-CD19 or anti-CD138 CAR.  
To summarize, the revolution of immunotherapy in cancer treatment in the last 
years is a field that is being incorporated to the treatment of MM. Among the 
different types of immunotherapy, the introduction of monoclonal antibodies 
targeting CD38 (daratumumab) and CS1 (elotuzumab) in combination with IMiDs 
or bortezomib has significantly improved the outcome of patients with R/R MM. 
Other monoclonal antibodies targeting IL6, CD56, CD138 and CD40 were tested 
but, unfortunately, did not show any benefit or just limited responses were 
observed. Moreover, immunocheckpoint inhibitors have not shown a beneficial 
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effect in MM patients, and additionally, high toxicities were detected. In the field of 
CAR-modified T cells, BCMA has proven to be the star among other CARs tested 
in MM and very promising clinical results are expected. It is expected that in the 
next decade, as new alternatives appear, novel combination of treatments will be 
tested and hopefully will lead to higher complete remission rates and prolonged 
survival in patients with MM along with the lowest possible toxicity. 
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2. MEMORY T CELLS 
2.1	General	informations	about	memory	T	cells	
	 When naïve T-cells meet cognate antigen in the draining lymph node (LN), the 
cells undergo activation and proliferation program, and differentiate into a 
heterogeneous population of effector T-cells. These effector T cells then migrate to 
the site of infection and eliminate pathogen-infected cells. Most effector cells die 
after clearance of the pathogens but some cells, subsequently, can differentiate into 
memory T-cells. During the immunological activity, T-cells receive specific signals 
that impact their ultimate fate; either death or differentiation into different types of 
memory cells with distinct functional and migratory properties [35, 36]. T-cells with 
weak stimulatory potential preferentially remain in the LN and differentiate into 
central memory T-cells (TCM cells) where they survey lymph and blood [37]. Instead, 
T-cells with high stimulatory potential differentiate into potent effector cells that 
migrate to inflamed tissues and subsequently die.  
 The effectors that do not receive these tissue-instructive signals may differentiate 
into effector memory T-cells (TEM cells) that circulate between blood and certain 
peripheral tissues. Instead, some effector cells receive tissue-specific instructive 
signals to differentiate into tissue-resident memory T-cells (TRM cells) and establish 
permanent residency within the tissues [38].  
 TEM cells play a supportive role to TRM due to an immediate effector functions and 
their ability to rapidly move to infection sites.  
 The external or internal surfaces of the body such as the skin and the mucosal 
linings of the gastrointestinal, respiratory, and urogenital tracts are a major gateway 
for infectious pathogens to access to the body.  
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 Inside these tissues reside different types of immune system cells, such as 
macrophages, dendritic cells (DC), γδ T-cells, and innate lymphoid cells (ILC), and 
they play important roles in maintaining the integrity of these epithelial barriers. 
 Accumulating evidence has revealed that there are dynamic and complex 
interactions between TRM cells in peripheral tissues and the original resident cell 
populations. For example, some tissue-resident immune provide to TRM cells factors 
for their maintenance [39, 40].  
 Furthermore, it is now known that TRM cells are also established in non-barrier 
tissues (such as the brain, liver, and kidney) as well as the primary lymphoid organs 
and secondary lymphoid organs (SLOs) and protect tissues from infectious 
pathogens disseminated by haematogenous or cellular pathways [41].  
 In all these locations we can found CD4+ and CD8+ memory T-cells but TRM cells 
are best characterized for the CD8+ subset and, therefore, it is to these that 
reference will mostly be made.  
  
 2.2	Tissue-Resident	Memory	CD8+	T	Cells	Phenotype	
Tissue-resident memory CD8+ T-cells was formally described in 2009. CD8+ TRM 
cells have been shown to stably reside in different tissues, where they provide rapid 
and potent protective immunity against re-infecting pathogens. Phenotypically, TRM 
cells constitutively express CD69, integrin αE(CD103)β7 (commonly referred to as 
CD103), CD45RA, CD8, CD3 and lake of CD62L and CCR7 [42, 43].  
Interestingly, CD69 expression is not limited to CD8+ T-cells, and it is also present 
on other immune subsets including natural killer cells. While CD69 is expressed on 
the majority of TRM subsets, absence of this lectin on CD8+ T-cells only limits the 
size of the population and does not result in complete ablation [44]. This suggests 
that CD69 is not an absolute requirement, and while its expression, although 
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advantageous, is not mandatory [45]. 
CD103 is the ligand for E-cadherin, which is expressed in epithelial cells. For this 
reason, is conceivable that CD103 is responsible for residency in epithelial tissues. 
Though physical retention by ligand binding is the best-known role for CD103, 
engagement of CD103 may have a number of other functional ramifications outside 
of adhesion. For example, the effects of CD103 binding have been also studied in 
tumor models. CD103+ tumor-infiltrating CD8+ T-cells are more capable of killing 
tumor cells [46]. This is likely attributed to the fact that CD103+ T-cells form more 
stable synapses with target cells than their CD103-negative counterparts [47]. 
Moreover, engagement of CD103 also positions cytolytic granules to organize in a 
polarized fashion, and the addition of signaling through the TCR results in lytic 
granule exocytosis [48, 49].  
   
2.3	Tissue-Resident	Memory	CD8+	T	Cells	in	Non-Lymphoid	Organs		
2.3.1	Barrier	Tissues		 The skin is composed of three main layers, the epidermis, dermis, and subcutaneous 
fatty region and it represents one of the tissue sites in which TRM can reside. The 
epidermis and dermis are separated by a basement membrane and they harbor 
numerous populations of innate and adaptive immune cells. In detail, the hair 
follicles provide unique niches for immune cells including TRM cells [50].  
 Skin CD8+ TRM cells express canonical TRM makers such as the activation marker 
CD69, the E-cadherin- binding integrin CD103, and the collagen-binding integrin 
CD49a and, although are widely found throughout the body, their number is 
generally elevated at sites of infection and/or inflammation [51]. 
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	 In addition to the skin, TRM cells can also homing in the intestinal mucosa; this 
latter consists of a single layer of intestinal epithelial cells that overlies the lamina 
propria (LP), a thin layer of loose connective tissue. The epithelium and LP are 
separated by a basement membrane and each provides a distinct immunological 
niche for the maintenance of TRM cells. Significant numbers of antigen-specific TRM 
cells are established in the intraepithelial compartment following intestinal 
infections and most of them are CD8+ T cells. However, the accumulation of TRM 
cells is also evident even in the absence of intestinal infection [52], suggesting the 
presence of additional niches that sustain TRM cells in the infection/inflammation-
inexperienced LP.  
	 The migration of effector and memory T-cells into the mucosa of the Female 
Reproductive Tract (FRT) is significantly restricted in the absence of local infection 
and/or inflammation [53]. Once recruited, however, TRM cells are formed and 
maintained in both compartments under the control of local environmental cues. 
Distinct from the skin CD8+ TRM cells, however, the development and maintenance 
of CD8+ TRM cells in the FRT is IL-15-independent [54] and, currently, the factors 
that regulate the maintenance of TRM cells in the FRT are largely unknown. 
 Upper Respiratory Tract (URT) and Lower Respiratory Tract (LRT) are two other 
specific areas of TRM cell localization.	Most studies have largely focused on TRM 
cells in the LRT, but the most common airborne pathogens primarily infect the 
URT. Thus, understanding the TRM niches in both compartments is critical for the 
development of specific vaccines. The instructions required for the differentiation 
of CD8+ TRM cells in the nasal mucosa are different from those in the LRT. 
Furthermore, the number of CD8+ TRM cells in the nasal tissues is relatively stable 
(it was the same 3 months post-infection), whereas there is a significant decline in 
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number of these cells in the LRT (lung). This suggests the existence of different 
niches of CD8+ TRM cells maintenance between URT and LRT [55].  
 Finally, among barriers tissues, it is also possible to observe the presence of TRM 
cells in the Salivary Glands (SGs), exocrine epithelial tissues that secrete saliva into 
the oral cavity.	It is known that the SGs can be a target of several bacterial and viral 
infections, for example cytomegalovirus (CMV).  In latently infected individuals, 
resident populations of antigen-specific CD8+ and CD4+ TRM cells are located in 
the SGs.  CD4+ TRM cells are observed predominantly in the stroma of the SGs [56], 
while CD8+ TRM cells, that express CD103, are located in the epithelium of the 
acini and ducts [57]. These TRM cells can confer protection upon recall by 
eliminating CMV infected non-epithelial cells, where CMV fails to achieve 
complete downregulation of MHC class I molecule.  	
2.3.2 Non-Barrier Tissues 
The presence of TRM, as cells responsible for immunological surveillance, it was 
also observed in Non-Barrier Tissue, including the brain. The presence of the 
blood–brain barrier (BBB) makes the central nervous system (CNS) an immune 
privileged site with severely limited ingress of blood-borne T lymphocytes and few, 
if any, T-cells are present in the healthy brain parenchyma under non inflammatory 
conditions. For this reason, the accumulation of T-cells in the brain parenchyma has 
generally been considered a pathological condition [58]. However, it is now known 
that few peripheral T cells can be present in the brain in the absence of 
inflammation and they play there a key role in surveying the CNS [59], as the lack of 
these cells can result in opportunistic infections in the CNS [60]. Among these T-
cells, it is possible to observe also in the brain la presence of TRM cells.  These last 
		 26	
are primarily established at brain surface structures, such as meninges and confer 
protection against reinfection [61]. 
In addition to the brain, the presence of TRM cells was also observed in the liver and 
kidney.  
Recent studies have demonstrated that liver-resident memory CD8+ T-cells are 
established in the sinusoid following systemic infection or vaccination [62] and are 
present in both, healthy and hepatitis B virus infected individuals.		
Lymphocytes are relatively rare in healthy kidneys but a small numbers of resident 
immune cells such as macrophages and T-cells can be found in the interstitium in 
normal condition. CD8+ TRM cells can be observed in extravascular renal 
compartments following direct [63] or regional infections with pathogens, where 
they seem to play an important role in immunological surveillance against possible 
reinfections 
Finally, the presence of TRM cells also in White Adipose Tissue (WAT) and in 
some solid tumors tissue has been described. In this last case, it appears that TRM 
cells may also have a protective role for the tumor, but this protection is limited to 
primary tumors, and not metastases, since CD8+ TRM cells are segregated from the 
circulation [64]. 	
2.4	Tissue-Resident	Memory	CD8+	T	Cells	in	Lymphoid	Organs		 In addition to the anatomical sites mentioned above, TRM cells can be also observed 
in Lymphoid Organ (LO), both in Secondary Lymphoid Organs (SLOs), like 
lymphnodes and spleen, and Primary Lymphoid Organs, such as thymus and bone 
marrow.  
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 2.4.1	Secondary	Lymphoid	Organs	(SLOs)	
	 Lymphnodes, Spleen		 The SLOs have generally been considered a transit place for TCM and TEM cells. 
However, recent studies have demonstrated that there are also small numbers of 
memory CD4+ and CD8+T-cells that are resident in the LN, spleen and tonsils 
without recirculation [65]. Unlike circulating memory T cells, TRM cells in the SLO 
share phenotypic characteristics and gene expression profiles with those in the non-
lymphoid tissues, including the expression of CD69. Since surface expression of 
CD69 is generally transient, however, it is likely that repetitive antigen stimulation 
is required for the maintenance of CD69 expression and the retention of TRM cells 
in the SLO [66]. In this regard, there is considerable evidence that residual antigen 
persists in the draining LN for several months after vaccination or the resolution of 
an acute infection and presumably facilitates the accumulation of memory T-cells 
[67]. The distribution of TRM cells in the SLO depends on an antigen niche and the 
TRM cells are preferentially localized at the common antigen entry sites: the 
marginal zone and red pulp of the spleen and the subcapsular sinuses of the LN [68]. 
TCM cells in the SLO have a critical role in the pathogen clearance by generating 
massively increased numbers of secondary effector T cells during a recall response. 
For this reason, it will be important to determine the functional contribution of TRM 
cells in the SLOs during the recall responses. It is possible that TRM cells in the 
SLO do not actively contribute to the recall response to avoid unnecessary 
competition with TCM cells, but are strategically positioned to protect the SLO from 
direct infection with pathogens.		
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2.4.2.	Primary	Lymphoid	Organs	
	 Thymus	
	 CD8+TRM cells have also been found in the thymus, a primary lymphoid organ [69]. 
Thymic CD8+ TRM cells are observed after a specific infection with either thymus-
tropic or non-tropic pathogens. As with TRM cells in the peripheral tissues, thymic 
CD8+ TRM cells exhibit a canonical TRM phenotype (CD69+, CD103+). These cells 
are located predominantly in the medulla although a few cells lodge also in the 
cortex. The immune activation process strongly inhibits the migration of peripheral 
dendritic cells populations to the thymus to avoid unfavourable induction of 
acquired tolerance to the invading pathogens [70] and for this reason, it is reasonable 
to think that thymic CD8+ TRM cells mainly function to protect the thymus, rather 
than contribute to the recall responses against systemic infections. 		 Bone marrow	
	 As mentioned above, when a pathogen attacks a barrier tissue, primary immune 
responses are initiated in the draining lymph nodes (LN) and sometimes in the 
spleen. In the secondary lymphoid organs, mature antigen-presenting dendritic cells 
(DC) prime T-cells to undergo huge clonal expansion and differentiation into short-
lived effector and long-lived memory T-cells. Both types of antigen experienced T 
cell display an increased capacity to migrate to inflamed tissues as well as to the 
BM as compared with naive T-cells. Memory T-cells can be found all over the 
body, with a peculiar enrichment also in the BM. The BM consists of islets of 
hematopoietic BM interspersed with fatty areas, all contained within spongy bone 
and inside central cavities of long bones. In healthy individuals BM contains 
mature T-cells that represent about 3–8% of total nucleated BM cells, and have a 
typically reduced CD4/CD8 T cell ratio, as compared with blood [71, 72]. The BM 
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contains several memory-phenotype T-cells, a cellular subset defined by the 
expression of activation/memory markers, including memory T-cells specific for 
previously encountered antigens. BM memory T-cells contain both central memory 
and effector memory T-cells [73, 74]. Thus, the BM is often described as a “reservoir” 
for long-lived memory T-cells [75, 76]. Some pivotal experiments suggest that the 
BM represents a temporary stopping point for recirculating memory T-cells but it 
also possible to observe TRM [77]. About the homing molecules into the BM of 
memory T-cells, memory CD8 T-cells slow down and roll in BM microvessels via 
L-, P-, and E-selectin-mediated interactions; CD4 T-cells lodge into the BM via 
molecular mechanisms similar to those of CD8 T-cells but, for their retention in the 
BM the expression of β1-integrin by CD4 T-cells is required. Furthermore, is now 
also known that CD69 regulates local T-cell retention in the BM by different 
mechanisms. 
 Memory T-cells specific for previously encountered antigens are commonly found 
in the BM of healthy subjects as well as of individuals affected by infectious, 
immune-mediated, and neoplastic diseases. For example, specific CD4 and CD8 T-
cells were present in the BM of immune individuals after resolution of acute 
infections but also in the BM of subjects infected by persistent viruses, including 
Cytomegalovirus (CMV), Epstein–Barr Virus (EBV), and Human Hepatitis C Virus 
(HCV) [78, 79]. Also BM from neoplastic patients can contain tumor antigen-specific 
T-cells.  
 BM memory T-cells present some phenotypic differences respect to corresponding 
cells from lymphoid periphery and blood. For example, a high proportion of CD4 
and CD8 BM memory T-cells express CD69, but no critical differences were found 
by gene-expression analysis of memory T-cell paired samples obtained from either 
BM or blood/spleen.  
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 In respect to the activity status, the majority of BM memory T-cells are quiescent, 
as demonstrated by staining with the cell cycle marker Ki67, but a small percentage 
of them divides under steady state. For example, CD8 T-cell proliferation in the 
BM is supported by local stimuli, including a dominant role for IL-15 [80].  
 About the function, as demonstrated by adoptive transfers in immunodeficient mice 
[81] and in vitro studies [82], BM memory T-cells perform a potent antigen-specific 
effector function. As evidenced in several papers available in the literature [83, 84], 
memory T-cells from BM of patients with different solid and hematological cancers 
were able to kill autologous tumor cells. Moreover, T cell-derived cytokines can 
modulate hematopoiesis, implying that BM T-cells can contribute to shaping 
hematopoiesis during both acute and chronic infections [85].  
	 Finally, T-cells can regulate physiological processes occurring in the BM, like 
normal hematopoiesis and bone tissue homeostasis. Surprisingly, in physiological 
conditions, T-cells promote the maintenance of normal bone mass and bone mineral 
density stimulating the production of the RANK-L decoy receptor osteoprotegerin 
by B cells, through CD40L/CD40 interaction [86]. Therefore, a cross-talk between 
T-cells and hematopoietic precursors occurs in the BM also in normal healthy 
conditions [87, 88]. 
 
2.5	Concluding	remarks			 The identification of recirculating memory T-cells and TRM cells offers a novel 
view of both memory maintenance and response to antigenic re-challenge, with a 
broader view respect to the previous perspective based on TCM/TEM paradigm [89]. 
Recirculating memory T-cells rely on a finely tuned equilibrium between 
quiescence and homeostatic proliferation, in several tissues wherein these cells can 
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temporarily stop. In contrast, TRM cells live permanently as non-migratory cells 
within some sites, including BM, wherein they survive in a quiescent state. 
 It appears that recirculating memory T-cells and TRM cells provide respectively 
systemic immunity and immediate protection against pathogens. The two types of 
memory T-cells act in concert for tissue protection, as recirculating memory T-cells 
are recruited with more efficient local effector response and boosting of systemic 
memory. Naturally, recirculating memory T-cells arrive with some delay in the 
tissue, while TRM cells are already there for highly efficient immediate protection. 
As TRM cells have been identified not only at the epithelial barriers of the body but 
also in lymphoid and/or internal organs, e.g., LN and brain, it is likely that each 
organ harbors some TRM cells and that BM is not an exception to this rule. Despite 
their different migration pathways, positioning and role in immunity, TRM cells 
participate in a local network of cellular and molecular interactions in the organ 
where they are located, influencing normal tissue homeostasis and organ function. 
In the case of BM T-cells, it has been shown that they normally regulate 
hematopoiesis, as well as bone metabolism. Instead, about TRM cells located in 
barrier organs, it is conceivable that they protect host’s health and sometimes 
contribute to disease in several manners, for example they might shape the gut 
microbiota composition, with a possible indirect impact on metabolic syndrome, 
obesity-related disorders, inflammatory bowel disease, and colorectal cancer [90]. 
 
2.6	Unsolved	questions	
Despite the current and specific knowledge regarding the characterization and role 
of memory T-cells, there are still unsolved questions. For example, what are the 
distinct signals regulating differentiation of either recirculating memory T-cells or 
TRM cells? And where and when do they receive them?  
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Another question still open is that relating to intracellular networks orchestrating 
differentiation. We do not know yet the single molecules and/or molecular 
pathways involved in gene transcription, protein translation and metabolic state of 
TRM and of recirculating memory T-cells.  
Finally, are there changes occurring with aging in the number and activity between 
TRM and recirculating memory T-cells? 
Further investigation is needed in order to better understand the biology and 
specific functions of this memory subset of T-cells.  
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3. PHENOTYPICAL CHARACTERIZATION STUDY AND 
FUNCTIONAL ANALYSIS OF BONE MARROW TISSUE-
RESIDENT MEMORY CD8 + T CELLS IN MULTIPLE 
MYELOMA PATIENTS 
 
3.1	Background	
One of the main features of the immune system is the "immunological memory", 
with the possibility, following exposure to a specific antigen, to enhance the future 
ability to respond to that same antigen with a more rapid secondary immune 
response and more intense. This immune memory is achieved because the memory 
cells, derived from both B and cellular T, are more efficient than virgin cells. 
In the group of the T lymphocyte population, the naïve T-cells, once activated by an 
antigen, undergo an enormous clonal expansion and at the same time differentiate 
into a short-lived effector, which generally die at the end of the immune response, 
and in long-lived memory cells (long-lived memory T-cells), ready to provide 
protection in case of new contact with the same antigen. Within T-cell memory 
pool, we can distinguish two cellular subgroups, in relation to the phenotype and 
functional potential:  TCM, which express the chemokine receptor CCR7 at high 
intensity, and TEM, which do not express the CCR7. Was also described a group of 
non-circulating resident T cells, TRM, which live permanently in some peripheral 
tissues where they survive in a state of quiescence.  
It appears that circulating memory T-cells are responsible for systemic immunity, 
while TRM cells represent immediate protection in the main entry sites of the 
pathogen, mostly participating in local defence. 
Recent studies have shown that also in the BM is possible to observe the presence 
of TRM cells. Indeed, BM is able to provide survival signals by promoting the 
interaction among TRM cells and stromal cells expressing homeostatic cytokines, 
such as IL-7 or IL-15. 
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In addition to their activity in local defence, has recently been highlighted the 
possibility that TRM may contribute to the defence of the host in the neoplastic 
diseases, representing potentially reactive cells against some hematological tumors 
infiltrating the BM [91].	 In relation to this last topic, we conducted a prospective 
population-based study aimed at evaluating the frequency, phenotype and 
functional analysis of T CD8 + memory cells residing in BM of subjects with a 
diagnosis of MM.  
In functional analysis we evaluated the CD107a/b and NKG2D expression on the 
surface of BM CD8+ TRM.  
Cancer development is under surveillance by the immune system of the host and 
the tumor cells can be recognized and killed by the immune secretion of lytic 
granules from CD8+ T lymphocytes. This process involves the fusion of the 
granule membrane with the cytoplasmic membrane of the immune effector cell, 
resulting in surface exposure of lysosomal-associated proteins that are typically 
present on the lipid bilayer surrounding lytic granules, such as CD107a/b. 
Therefore, membrane expression of CD107a/b constitutes a marker of immune cell 
activation and cytotoxic degranulation [92]. For this reason, in order to evaluate the 
possible cytotoxic immune function of BM CD8+ TRM against cancer cells we also 
evaluated the CD107a/b expression on their cell surface, after functional 
stimulation with activation molecules. 
Finally, as several data in the literature highlight the presence of MICa and b 
ligands on myelomatous plasma cells [93], in order to evaluate one possible 
cytotoxicity pathways, we performed the cytometry evaluation of NKG2D on the 
surface of BM CD8+ TRM isolated.  
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3.2	Materials	and	methods		
3.2.1.	Population		
The study population was represented by 21 consecutive patients with new 
diagnosis of MM, with a diagnosis made between September 1, 2018 and August 
31, 2019. All patients were followed in the Hematology Division of the AOUP "P. 
Giaccone" of Palermo". Patients with IgA, IgG and LCMM aged over 18 years 
were included. While, patients with liver cirrhosis, with another type of 
concomitant neoplasm or with another diagnosis of tumor disease made in the two 
years prior to hypothetical enrolment were excluded. 
Clinical and laboratory data concerning the patient's characteristics and blood 
disease, also essential for assessing the patients eligibility, were collected through 
specific data bases and the consultation of medical records.  
The biological study was carried out on bone marrow samples taken in quantities of 
4 cc during the BM analysis phase, to which all patients were subjected for the 
suspected diagnosis. 
Specific written informed consent was requested from the patients, in accordance 
with institutional and national requests, for the processing of personal data and 
above all for carrying out the planned biological investigations. 
The laboratory part of the study, especially in relation to the flow cytometric 
analysis and the functional study was conducted at the "Central Laboratory for 
Advanced Diagnosis and Biomedical Research (CLADIBIOR) and Department 
Bi.N.D." of the AOUP "P. Giaccone" of Palermo.  
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3.2.2.	Flow	cytometry	analysis			
The evaluation ex vivo of CD8 TRM frequency and phenotype in BM samples was 
performed using anti-human mAbs to CD3 (FITC, REA Clone 613 from Miltenyi 
Biotech), CD103 (PE, REA Clone 803 from Miltenyi Biotech), CD69 (PE-Vio615, 
REA Clone 824 from Miltenyi Biotech), CD45 (PerCP-Vio700, REA Clone 747 
from Miltenyi Biotech), CD8 (PE-Vio770, REA Clone 734 from Miltenyi Biotech), 
CD45RA (Viogreen, REA Clone T6D11 from Miltenyi Biotech), CCR7 (CD197) 
(Vioblue, REA Clone 546 from Miltenyi Biotech), Ki67 (APC, REA Clone 183), 
Zombie NIR Fixable Violability kit Biolegend Cat.n. 423103. For the surface 
staining were used 2 ml of each monoclonal antibody. After 20 min. of incubation 
at RT the sample were washed and then were added 2 ml of 7AAD for the 
exclusion of death cells. After 5 min. the cells were re-suspended in PBS and 
acquired on FACSARIA I (BD Biosciences). The sequential gating strategy was: 
gate on lymphocytes population with CD45 vs SSC, 7AAD negative cells, 
exclusion of doublets with FSC-H vs FSC-A, CD8+CD3+ and evaluation of 
percentage of CD103+CD69+ cells. Was also established the subsets using CCR7 
and CD45RA (Fig. 1). 		
3.2.3.	In	vitro	assay		
BM derived mononucleate cells from MM patients were then coltured in vitro in 
complete RPMI with 10% of human serum for 4 days with IL15 (25 ng/ml), IL7 
(25 ng/ml) and TGFβ (2 ng/ml) in different combination and in RPMI alone. After 
colture we analysed the frequency of CD8 TRM and the proliferating fraction with 
intracellular staining with anti human Ki67 APC (from Miltenyi Biotech). 
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3.2.4.	Functional	analysis	by	cell	stimulation		
Fresh BM mononuclear cells (BM MNC) were isolated using Hypaque-Ficoll 
(Cederlane) density centrifugation. In some instances BM MNC were frozen (90% 
fetal calf serum (FCS)/10% DMSO) at −160 °C until use. 5x105 BM MNC were 
incubated with 750 ng/ml of ionomicin and 150 ng/ml of phorbol 12-myristate 13-
acetate (PMA) (Sigma Aldrich). FITC conjugated antibodies to the lysosome 
associated membrane proteins (LAMPs) CD107a (Anti-human CD107a -LAMP 1-, 
FITC, eBioH4A3 Clone, eBioscience) and CD107b (Anti-human CD107b -LAMP 
2-, FITC, eBioH4B4 Clone, eBioscience) were added to the cells prior to 
stimulation according to the manufacturer instructions. A negative control was 
included to evaluate the spontaneous expression of CD107a/b. The cells were 
incubated for 1 h at 37 °C in a 5% CO2 incubator, followed by an additional 4h in 
the presence of the secretion inhibitor monensin (BD Pharmingen). After 
incubation samples were acquired on FACSAria flow cytometer (BD bioscence) 
and analyzed by Flowjo software. 
Finally, in order to evaluate one possible cytotoxicity pathways, we studied the 
expression of NKG2D (CD314) (FITC, REA Clone 797 from Miltenyi Biotech) on 
BM CD8+ TRM isolated from the samples under examination. 		
3.2.5.	Statistical	analysis	
	Non-parametric	 Mann-Whitney	 and	 Kruskall-wallis	 tests	 were	 performed	 to	determine	 statistical	 differences	 in	 the	 distribution	 of	 the	 results	 using	GraphPad	Prism	7.00.	Values	of	*	p<0.05	were	considered	significant.					
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3.3	Results		
In our study we collected data from 21 patients with new diagnosis of MM, 
followed in the Hematology Division of the AOUP "P. Giaccone" of Palermo. The 
study sample consisted of 11 males and 10 females, with a median age of 68 years 
(range 51 to 82). In the patients group, 7/21 had a multiple myeloma with isotype 
IgG k, 6/21 IgG λ, 2/21 IgA k, 2/21 IgA λ and 4/21 had LCMM λ.  
In relation to the staging, 11/21 (52,4%) patients had ISS III, 5/21 (23,8%) had ISS 
II and 5/21 (23,8%) had ISS I.  
The characteristics of patients are shown in table 1. 
Cytofluorimetric analysis performed on bone marrow blood samples showed that 
the ex vivo average frequency of CD8+ TRM was of 0.48% and the phenotype was 
represented mainly by TEM (72,9%) followed by TEMRA (12.3%) and (7,6%) of 
naïve cells and (7,2%) of TCM (Fig. 2). To evaluate factors capable of maintaining 
or to induce the expansion of these cells in vitro, we maintained BM-derived 
mononucleate cells from MM patients for 4 days in presence of homeostatic 
cytokines, IL-15, IL-7 plus IL-15 and IL-7 together with IL-15 and TGF-β. The 
result showed an increase of the percentage of CD8+ TRM in all conditions tested, 
especially in presence of all cytokines (Fig. 3), with a percentage of CD8 TRM of 
2,74%. Regarding the phenotype distribution, we observed an expansion of CM 
compared to the other subsets (Fig. 4). We also analysed the percentage of CD8+ 
TRM proliferating through the identification of Ki67 positive cells. Data highlight 
that IL-15 gives the strongest proliferative input, but also other cytokines contribute 
to the homeostatic maintenance of these cells (Fig. 5).  
In order to evaluate the possible cytotoxic immune function of BM CD8+ TRM 
against cancer cells we also evaluated the CD107a/b expression on their cell surface 
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after stimulation with activation molecules. This functional analysis highlights that 
BM CD8+ TRM, after stimulation/activation, show degranulation, indirect signal of 
possible cytotoxic activity (Fig. 6). 
Finally, in order to explore one possible pathways of this cytotoxicity, we studied 
the cytofluorimetric expression of NKG2D on BM CD8+ TRM with the evidence of 
expression of this marker on the surface of these cells (Fig. 7).  
	
	
	
Table	1.		Patients	characteristics	
(N=	21)	
Characteristics		 					N.	patients															%	
Sex:	M	 11	 	52,4	F	 10	 	47,6	
Age:	≤	70	anni	 12																														57,2	>	70	anni	 9																																42,8	
MM	Isotype:	IgG	k	 	7	 		33,3	IgG	λ	 	 	 	 	 	 	 													6	 	 			28,6	IgA	k	 2	 9,5	IgA	λ		 	2																																	9,5	Light	chain	k	 	0			 			0,0	Light	chain	λ	 	4	 			19,1	
MDE	(Myeloma	Defining	Events):	HyperCalcemia		 	 	 	 	 														2	 	 				38,1	Renal	Failure	 4	 19,0	Anemia	 9	 42,8	Bone	Lesions	 16	 76,2	Bone	Marrow	Plasma	cells	≥60%	 11	 52,4	FLC	ratio	≥100	 12	 57,1	
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≥1	focal	lesion	in	MRI	(>5	mm)	 					8																														38,1	 	
ISS:	I	 5	 		23,8	II	 5	 		23,8	III	 11	 		52,4	
ECOG:	0-1	 18	 85,7	2-4	 		3	 14,3		 	 	 																																							Fig	1:	gating	strategy	
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				Fig.	2:	Ex-vivo CD8+ TRM phenotype distribution	
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Fig.	3:	Increase of CD8+ TRM after in vitro culture with IL7 + IL15 +TGF-β 
 
		Fig.	 4:	 CD8+TRM phenotype distribution after 4 days culture with IL7 + IL15 
+TGF-β		
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Fig. 5: proliferative input from homeostatic cytokines  	
		Fig.	6:	increased expression of CD107 a/b on the surface of BM CD8+ TRM cells 
after incubation in the presence of the secretion inhibitor monensin 	
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Fig.	7:	cytofluorimetric expression of NKG2D. Red: isotypic control; Blue: NKG2D 
expression on BM CD8+ TRM. 		
			
4. DISCUSSION 	
An important potential of our immune system is represented by "immunological 
memory", capable of inducing a faster and more intense secondary immune 
response towards an already known antigen. Both cell B and cell T cells mediate 
this immunological memory. 
In the context of the lymphocyte T population, long-lived memory T-cells have 
been described and they provide protection in case of new contact with the same 
antigen. These memory T-cells can be localized in any part of the body and some of 
them, the TRM cells, live permanently in some peripheral tissues, including the bone 
marrow. 
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In recent years, from some papers in the literature, data have emerged about the 
possible ability of these cells to contribute to the defence of the host in the 
neoplastic field, representing potentially reactive elements against hematological 
tumors infiltrating the marrow. 
Therefore, in relation to this last topic, we conducted a prospective study in order to 
analyse the TRM cells in the bone marrow of patients with a new diagnosis of 
multiple myeloma. 
The main objective is to evaluate the frequency and phenotype of resident CD8 + 
memory T lymphocytes and also perform a functional study. In fact, CD8 + TRM T 
lymphocytes may be able to control tumor growth and, therefore, they can represent 
a potential target in the context of the most modern immunotherapy. 
At first, from the analysis we found that the ex vivo average frequency of CD8+ 
TRM was of 0.48% and the phenotype was represented mainly by TEM (72,9%).  To 
evaluate factors capable of maintaining or to induce the expansion of these cells in 
vitro, we maintained BM-derived mononucleate cells in presence of homeostatic 
cytokines, IL-15, IL-7 plus IL-15 and IL-7 together with IL-15 and TGF-β, with an 
increase of the percentage of CD8+ TRM in all conditions tested and in presence of 
all cytokines, especially under the proliferative input of IL-15.  
In order to evaluate the possible cytotoxic immune function of BM CD8+ TRM 
against cancer cells we also evaluated the CD107a/b expression on their cell surface 
after incubation with activation molecules. This functional analysis highlights that 
BM CD8+ TRM, after stimulation/activation, show degranulation, indirect signal of 
possible cytotoxic activity.  
Finally, in order to explore one possible pathways of this cytotoxicity, we studied 
the cytofluorimetric expression of NKG2D on BM CD8+ TRM and the 
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cytofluorimetric analysis shows the expression of this marker on the surface of BM 
CD8+ TRM.  	
5. CONCLUSIONS 
 
It appears that circulating memory T-cells are responsible for systemic immunity, 
while TRM cells represent immediate protection in the main entry sites of the 
pathogen, mostly participating in local defence. 
Recent studies have shown that also in the BM is possible to observe the presence 
of TRM cells, especially CD8+ TRM, where, in addition to their activity in local 
defence, they may contribute to the defence of the host in the neoplastic diseases.  
The latter possibility acquires considerable value in the therapeutic management of 
the patients with hematological neoplasms infiltrating the marrow, including MM. 
BM CD8+ TRM cells could in fact represent an important therapeutic target, with 
the possibility of further improving the results of immunotherapy with the hope of 
increasing the response rate to the treatment of patients. 
Therefore, we evaluated the frequency and the phenotype of CD8 TRM in BM of 
MM patients and we performed a functional analysis of these cells. In MM patients, 
the increase of CD8+ TRM cells with a CM phenotype after in vitro culture with the 
three cytokines could have an anti-tumor role in the control of MM. Furthermore, 
the expression of CD107 after functional stimulation and the NkG2D expression 
show the ability of CD8+ TRM cells to perform cytotoxicity. Further studies are 
needed to investigate the cytotoxic capacity of these cells against myeloma cells, in 
order to study their functional role, also in the perspective of a possible use in 
future therapeutic programs.  
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